Accueil   Diary - News   All news Inclusion of the first patient in the TEMOkids pediatric clinical trial

Inclusion of the first patient in the TEMOkids pediatric clinical trial



Paris and Lyon, on May 4th, 2021 – ORPHELIA Pharma, a French biopharmaceutical company dedicated to the development and marketing of pediatric and orphan drugs, announces the inclusion of a first patient in the TEMOkids pediatric clinical study. The TEMOkids study aims to determine the pharmacokinetic parameters, tolerance, acceptability and response to treatment of Kimozo®, the first oral suspension of temozolomide, in the pediatric population (



Temozolomide is an anti-cancer drug used in treatment regimens for refractory or relapsed neuroblastoma that mainly affect very young children. It is also used to treat rhabdomyosarcoma and certain brain tumors. The only oral forms of temozolomide currently available are capsules which are not suited to children. In fact, to be administered, the capsules must be opened and their content added to food. In young children, the formulation is essential to ensure correct medication intake, safety, accuracy of the delivered dose and adherence to treatment. To meet the requirements of onco-pediatricians and the needs of children, ORPHELIA Pharma, working in close collaboration with Gustave Roussy hospital teams, has developed Kimozo®, the first ready-to-use drinkable suspension of temozolomide.



Read the press release